Genetic Risk Classification for Adults With Aml Receiving Less-Intensive Therapies: The 2024 ELN Recommendations

Authors

Hartmut Döhner
Courtney D DiNardo
Frederick R Appelbaum
Charles Craddock
Hervé Dombret
Benjamin L Ebert
Pierre Fenaux
Lucy A Godley
Robert P Hasserjian
Richard A Larson
Ross L Levine
Yasushi Miyazaki
Dietger Niederwieser
Gert Ossenkoppele
Christoph Röllig
Jorge Sierra
Eytan M Stein
Martin S Tallman
Hwei-Fang Tien
Jianxiang Wang
Agnieszka Wierzbowska
Andrew H Wei
Bob Löwenberg

Language

English

Publication Date

11-21-2024

Journal

Blood

DOI

10.1182/blood.2024025409

PMID

39133932

Abstract

The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.

Keywords

Humans, Leukemia, Myeloid, Acute, Adult, Risk Assessment, Genetic Predisposition to Disease, Risk Factors

Published Open-Access

yes

Recommended Citation

Döhner, Hartmut; DiNardo, Courtney D; Appelbaum, Frederick R; et al., "Genetic Risk Classification for Adults With Aml Receiving Less-Intensive Therapies: The 2024 ELN Recommendations" (2024). Faculty, Staff and Student Publications. 5589.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5589